CAMBRIDGE, Mass.--(BUSINESS WIRE)--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that it has initiated a two-stage, Phase 1/2 therapeutic clinical trial for Azedra™ (Ultratrace™ iobenguane I 131 or Ultratrace MIBG), for the treatment of malignant pheochromocytoma, a type of neuroendocrine cancer. The clinical trial is designed to determine therapeutic dosing and evaluate the safety and efficacy of Azedra, a targeted radiotherapeutic which consists of the known I-131-MIBG molecule radiolabeled using the company’s proprietary UltratraceTM technology.
